Mary is the head of Womble Bond Dickinson’s Life Sciences and Pharmaceuticals sector, which is a multi-disciplinary team focusing on pharmaceuticals, animal health, biotechnology, medical devices, biodefense, and other life sciences industry companies. Mary has been involved with the life sciences industry for more than 30 years, and has served as a trusted advisor and legal advocate for numerous clients, including representing her clients in litigation before various district courts and the Federal Circuit.
Mary and her team’s successes led the IAM Patent 1000 to recognize the team’s success in patent litigations, noting that Mary’s “résumé is replete with ANDA and biologics wins.” She has been described as a “biotechnology beacon in the Delaware litigation landscape and a “go-to” attorney for ANDA litigation. For example, Mary has been lead or co-lead litigation counsel for various pharmaceutical companies and has litigated patents that cover new chemical entities, polymorphs, formulations, methods of treatment, dosing regimes, medical devices, and other pharmaceutical and life sciences patents. She has been lead counsel on multiple ANDA and biologics cases and understands the importance of coordinating ANDA litigation with parallel actions, including actions involving the FDA, post-grant proceedings, and world-wide patent prosecution and litigation actions.
In addition to her work in the biotechnology, pharmaceuticals, and life sciences industries, Mary has also represented clients in other areas (e.g., chemical and chemical manufacturing) in both state and federal court and in front of the USPTO. Mary has a deep knowledge of Delaware practice and was one of sixteen (16) attorneys who was asked to serve on the most recent District of Delaware’s Advisory Committee. In addition, Mary has served as Delaware counsel in various cases, including in non-practicing entity and trade secrets litigation.
